Granahan Investment Management LLC boosted its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) by 3.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,157,536 shares of the company’s stock after buying an additional 34,835 shares during the period. Granahan Investment Management LLC owned approximately 6.88% of Biomerica worth $2,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Biomerica during the 1st quarter valued at about $57,000. Fore Capital LLC grew its position in Biomerica by 67.4% during the first quarter. Fore Capital LLC now owns 49,680 shares of the company’s stock valued at $93,000 after buying an additional 20,000 shares during the period. Russell Investments Group Ltd. grew its position in Biomerica by 101.1% during the fourth quarter. Russell Investments Group Ltd. now owns 63,768 shares of the company’s stock valued at $214,000 after buying an additional 32,061 shares during the period. Perritt Capital Management Inc. grew its position in Biomerica by 170.0% during the first quarter. Perritt Capital Management Inc. now owns 67,500 shares of the company’s stock valued at $126,000 after buying an additional 42,500 shares during the period. Finally, MYDA Advisors LLC acquired a new stake in Biomerica during the first quarter valued at $138,000. 26.25% of the stock is owned by institutional investors and hedge funds.
Biomerica Stock Performance
BMRA stock opened at $1.17 on Monday. The firm has a market cap of $19.68 million, a PE ratio of -2.34 and a beta of -0.62. The firm’s fifty day moving average is $1.30 and its 200 day moving average is $1.57. Biomerica, Inc. has a one year low of $1.03 and a one year high of $5.25.
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
- Five stocks we like better than Biomerica
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 9/4 – 9/8
- Canada Bond Market Holiday: How to Invest and Trade
- The Best 5 Small Cap AI Companies to Buy Now
- Business Services Stocks Investing
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.